MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2025 International Congress

    Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the efficacy of safinamide as an adjunct therapy in improving motor symptoms and extending ON-time in patients with Parkinson’s disease (PD). Background:…
  • 2025 International Congress

    Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson’s Disease

    N. Ito, J. Ozawa, K. Kataoka, K. Matsuoka, T. Nakanishi, T. Wada, A. Ishida, M. Kanemoto, T. Oguchi, M. Tsuji, Y. Kiuchi, H. Murakami (Tokyo, Japan)

    Objective: This study aims to identify pre-treatment indicators for Parkinson’s disease (PD) patients who respond well to monoamine oxidase type B inhibitors (MAOBIs). ​​​​​ Background: MAOBIs,…
  • 2025 International Congress

    Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson’s Disease

    D. Rinaldi, E. Bianchini, S. Galli, G. Imbalzano, CA. Artusi (Rome, Italy)

    Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment…
  • 2025 International Congress

    A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson’s disease (DATSZ-PD study)

    M. Takahashi, J. Koh, T. Shimokawa, Y. Kajimoto, T. Takeshima, H. Ito (Hirakata, Osaka, Japan)

    Objective: To investigate the efficacy and safety for neuroprotection and disease modifying effect in  selegiline(SL) or zonisamide(ZN) by using UPDRS, PDQ-39 and DAT -SPECT  in…
  • 2025 International Congress

    L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion

    R. Serpa, K. Palsa, E. Tufano, T. Helmuth, S. Mills-Huffnagle, M. Kant, J. Connor (Hershey, USA)

    Objective: This study aims to investigate the impact of L-3,4-dihydroxyphenylalanine (L-DOPA) on ventral midbrain (VMB) iron levels under iron deficiency (ID) and repletion (IR) conditions…
  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • 2023 International Congress

    The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series

    XY. Li, TC. Yen, CT. Zuo, JW. Wang, JY. Lu, FT. Liu (Shanghai, China)

    Objective: In a longitudinal case series of patients with progressive supranuclear palsy (PSP), a chronic challenge with the irreversible MAO-B inhibitor selegiline was used to…
  • 2023 International Congress

    Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats

    P. Kumar, N. Baquer (New Delhi, India)

    Objective: The objective of this study was to determine the effect of 17 β-estradiol (E2) and progesterone (P4) on the activities of Na+ K+ ATPase, monoamine…
  • 2023 International Congress

    Selegiline drives autophagic secretion of α-synuclein

    Y. Nakamura, S. Arawaka (Takatsuki, Japan)

    Objective: Our aim is to elucidate how selegiline drives extracellular secretion of α-synuclein (αS) and whether selegiline-induced αS secretion affects cell-to-cell transmission of αS. Background:…
  • 2023 International Congress

    Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study

    P. Lorenzo-Barreto, I. Pareés, P. Pérez-Torre, S. Fanjul, JL. López-Sendón, F. Pérez-Trapote, A. Sáez-Marín, E. Stiauren-Fernández, á. Patiño-Patón, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

    Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley